Contents lists available at ScienceDirect



CME Review

Environmental control measures for the management of atopy



Annals

College

Meredith A. Dilley, MD^{*,†}; Wanda Phipatanakul, MD, MS^{*,†}

* Boston Children's Hospital, Boston, Massachusetts

[†] Harvard Medical School, Boston, Massachusetts

A R T I C L E I N F O

Article history: Received for publication September 28, 2015. Received in revised form December 22, 2015. Accepted for publication December 29, 2015.

INSTRUCTIONS

Credit can now be obtained, free for a limited time, by reading the review article and completing all activity components. Please note the instructions listed below:

- Review the target audience, learning objectives and all disclosures.
- Complete the pre-test.
- Read the article and reflect on all content as to how it may be applicable to your practice.
- Complete the post-test/evaluation and claim credit earned. At this time, physicians will have earned up to 1.0 AMA PRA Category 1 CreditTM. Minimum passing score on the post-test is 70%.

Overall Purpose

Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.

Learning Objectives

- At the conclusion of this activity, participants should be able to:
- Define major in-home allergens associated with allergic sensitization
- Describe methods of allergen abatement in the home environment specific to each allergen

Release Date: February 1, 2017

Expiration Date: January 31, 2019

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. **Planning Committee Members**

Meredith Dilley. MD (Author)

Wanda Phipatanakul, MD, MS (Author)

Anne K. Ellis, MD (Associate Editor)

Jonathan A. Bernstein, MD (CME Subcommittee)

Guha Krishnaswamy, MD (CME Subcommittee)

John J. Oppenheimer, MD (CME Subcommittee, Associate Editor)

Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)

Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Reprints: Wanda Phipatanakul, MD, MS, 300 Longwood Avenue, Fegan 6, Boston, MA 02116; E-mail: wanda.phipatanakul@childrens.harvard.edu. **Disclosures:** Authors have nothing to disclose.

```
Funding Sources: National Institutes of Health grants T32HD0757270 (to M.A.D.) and K24AI106822 (to W.P.).
```

http://dx.doi.org/10.1016/j.anai.2015.12.029

1081-1206/© 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Disclosure Policy

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/ investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI.

All identified conflicts of interest have been resolved.

Disclosure of Relevant Financial Relationships:

M. Dilley and W. Phipatanakul have nothing to disclose. M.H. Grayson has received research grants from Children's Research Institute/ Medical College of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, HRSA and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. A.K. Ellis has received research grants from Circassia, Sun Pharma Advanced Research, Merck, Novartis, Pfizer, and GlaxoSmithKline; has also been a consultant/advisor for Circassia, Merck, Novartis, and GlaxoSmithKline; and has been a speaker for Merck, Novartis, Takeda and AstraZeneca. J.A. Bernstein, G. Krishnaswamy have nothing to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. No unapproved/investigative use of a product/device is discussed.

Recognition of Commercial Support: This activity has not received external commercial support.

Copyright Statement: Copyright © 2017 American College of Allergy, Asthma & Immunology. All rights reserved. **CME Inquiries:** Contact the American College of Allergy, Asthma & Immunology at education@acaai.org or 847-427-1200.

Introduction

With the increasing prevalence of allergic airway disease in recent years, efforts have focused on the importance of environmental control measures to decrease morbidity and improve quality of life in the allergic population. Once allergy and asthma have been established, allergen abatement is an important aspect of managing the atopic population. We review current evidence of the role of environmental control and abatement measures for common allergens including furry animals, rodents, cockroach, dust mite, and mold.

The reader should be aware that comprehensive practice parameters for management of allergy to furry animals,¹ rodents,² cockroaches,³ and dust mites⁴ have been published from 2012 to 2014. In accordance with these parameters, important terms used throughout this review are *reservoir* and *facilitating factor*. For this purpose review, a *reservoir* is a confined area where allergen can concentrate, and a *facilitating factor* is a factor that promotes allergen production.^{1–4} This review does not discuss the role of primary prevention in the development of atopy and wheeze. This review focuses on evidence-based methods of allergen abatement strategies aimed at decreasing morbidity in sensitive individuals.

Furry Animals

Sensitization to furry animals has increased in recent years, especially to household pets. Environmental control measures aim to decrease dander in the environment. Pet removal is an effective way to decrease exposure to allergen. In a study of pet owners with asthma sensitized to furry animals, one group opted to remove their pet from the home and the other group opted to keep their pet. Those in the pet removal group had decreased airway hyper-responsiveness and decreased use of asthma controller medication after 1 year.⁵ Although pet removal from the home is an effective way to decrease exposure, most pet owners will not remove pets because of emotional attachment. Even after pet removal, residual allergen can persist. Further, dog and cat allergens are found in homes without pets.⁶

Cat

Fel d 1 is the major cat allergen; it is found primarily on skin and fur and is produced in sebaceous, anal, and salivary glands. Highly concentrated areas of cat allergen include upholstery, bedding, and carpet.¹ After removal of cats from the home,⁶ the decrease of Fel d 1 levels can be slow over time. Therefore, although removal of cat from the environment is important, other methods of allergen elimination are necessary.

Cat immersion washing has been shown to significantly decrease Fel d 1 levels but only for a short time.⁷ Washing must be repeated regularly to maintain effectiveness. Further, there is no proved clinical benefit from washing of cats alone. Cat and dog allergens are present on walls, and efficient removal of allergen from walls has been demonstrated through direct washing of walls or through the use of dust cloths.^{1.6} Use of high-efficiency particulate arrestance (HEPA) filters in addition to removal of cat from living room and bedroom areas can decrease the level of airborne Fel d 1 allergen, but the clinical benefits of this intervention vary.⁸ Because cat allergen is found on settled dust, aggressive interventions including carpet removal also can decrease the level of cat allergen.⁹ Therefore, techniques for decreasing dust, discussed later, can contribute to less cat allergen exposure.

Regular use of high-efficiency and standard vacuums can decrease the level of cat and dog allergens in settled dust and improve lung function, although health effects are variable.⁹ Mattress encasings can prevent passage of dust and cat allergen; encasings that are woven and have small pores might be more effective than nonwoven encasings.¹⁰ In sum, a combination of minimizing exposure to cat allergen (removing reservoirs, cat removal) combined with HEPA filters and frequent cleaning of the cat can decrease allergen exposure.

Dog

Can f 1 is the major dog allergen. Sebaceous glands secrete dog allergen, and Can f 1 is found in canine saliva, fur, and dander, and reservoirs for dog allergen include bedding, furniture, and carpeting.¹ Many patients allergic to dog report better tolerance of certain breeds over others, leading to various breeds being referred

Download English Version:

https://daneshyari.com/en/article/5645452

Download Persian Version:

https://daneshyari.com/article/5645452

Daneshyari.com